NCT06117020View on ClinicalTrials.gov

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

October 16, 2024

Study Completion Date

October 16, 2024

Conditions
Muscle SpasticityHypertonia, MuscleCerebral PalsyMultiple SclerosisStrokeHereditary Spastic ParaplegiaDystoniaSpinal Cord Injuries
Interventions
DRUG

MTR-601

Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors

Lead Sponsor

Motric Bio
All Listed Sponsors
lead

Motric Bio

INDUSTRY

NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals | Biotech Hunter | Biotech Hunter